Import from '@/components/mdx'

AOD-9604 and Cancer Risk: A Clinician's Review for Women

What Is AOD-9604 and Why Are Women Using It?

AOD-9604 is a 16-amino-acid synthetic fragment of human growth hormone, specifically residues 176 to 191 of the C-terminal region. It was originally developed by Monash University researchers in Australia to capture growth hormone's fat-burning properties without triggering the anabolic and metabolic effects that make full-length GH problematic as a weight-loss agent.

Women are increasingly requesting AOD-9604 through compounding pharmacies, particularly those managing weight in perimenopause, those diagnosed with PCOS-related metabolic dysfunction, and those who have not reached their goals on lifestyle changes alone. The appeal is straightforward: a targeted lipolytic agent that, at least in theory, does not raise blood glucose or suppress thyroid axis the way full-length GH can.

How It Is Thought to Work

The core claim is receptor selectivity. Full-length growth hormone binds the GH receptor, stimulates IGF-1 production from the liver, and drives both anabolic and lipolytic effects. Heffernan et al. (2001) demonstrated in mice that the C-terminal fragment does not activate the GH receptor and does not raise serum IGF-1, yet still reduces fat mass. The proposed pathway is activation of beta-3 adrenergic receptors in adipose tissue, which stimulates lipolysis and thermogenesis.

The Regulatory Reality

AOD-9604 was granted FDA Generally Recognized as Safe (GRAS) status as a food ingredient in 2014, a designation that is often misquoted as FDA approval for therapeutic use. It is not. No new drug application for AOD-9604 has been approved. It is currently available only through 503A compounding pharmacies, which means quality, sterility, and dosing consistency vary by pharmacy.

The Cancer Risk Question: What the Science Actually Shows

This is the section that matters most if you are considering AOD-9604. The cancer concern with any GH-related compound centers on IGF-1.

The IGF-1 and Cancer Connection

Insulin-like growth factor 1 (IGF-1) promotes cell proliferation and inhibits apoptosis. Chronically elevated IGF-1 is associated with increased risk of breast, colon, and prostate cancers in epidemiological data. A 2004 meta-analysis published in the Journal of the National Cancer Institute found women in the highest IGF-1 quartile had approximately a 1.65-fold increased risk of premenopausal breast cancer compared with women in the lowest quartile.

Full-length GH therapy raises IGF-1. If AOD-9604 also raised IGF-1, that would be a clear risk signal. The central preclinical argument for AOD-9604's safety is that it does not.

What the Heffernan 2001 Data Actually Show

Heffernan et al. (2001) treated obese mice with AOD-9604 and measured body composition, IGF-1 levels, glucose tolerance, and lipid profiles. Mice receiving AOD-9604 lost significantly more adipose mass than controls without a measurable rise in serum IGF-1. Glucose tolerance was not impaired. Those findings were replicated across several dose groups.

This is the foundation of the "AOD-9604 does not carry GH cancer risk" argument. But the limitation is significant: mice are not women, the study ran for weeks not years, and mammary gland tissue, estrogen receptor expression, or hormone-sensitive tumor lines were never evaluated.

The Missing Human Carcinogenicity Data

Here is a framework for thinking through AOD-9604 cancer risk that does not appear in any competitor review: there are three distinct risk categories women should evaluate separately rather than treating "cancer risk" as a single yes/no question.

Category 1: IGF-1-mediated proliferative risk. Current animal evidence suggests AOD-9604 does not raise IGF-1. This is the strongest available safety signal, but it rests entirely on preclinical data. No phase II or phase III human trial has measured IGF-1 over a clinically meaningful duration (12 months or more) in humans.

Category 2: Direct receptor interactions in hormone-sensitive tissue. Beta-3 adrenergic receptors are expressed in breast adipose tissue. Whether AOD-9604 activates these receptors in the human mammary gland, and whether that has downstream effects on estrogen metabolism in adipose stroma, has not been studied. This is not a confirmed risk. It is an open question.

Category 3: Off-target peptide activity. Compounded peptides often contain impurities or degradation products. Without pharmaceutical-grade manufacturing controls, a compounded AOD-9604 preparation could contain fragments with different receptor-binding profiles than the studied compound.

Phase III Program and Its Abandonment

Metabolic Pharmaceuticals Ltd. (Australia) ran the compound through phase IIb/III trials for obesity between approximately 2001 and 2007 before discontinuing development. A summary of that program noted the primary efficacy outcomes were modest, and the company pivoted rather than continuing toward an NDA. The trial data from those phase II/III runs have not been fully published in peer-reviewed form. That means the carcinogenicity and long-term safety data collected in human subjects remain largely inaccessible to clinicians. This is an evidence gap women deserve to know about explicitly.

How Women's Hormonal Status Changes the Risk Picture

Reproductive Years and PCOS

Women with PCOS often have elevated basal IGF-1 and hyperinsulinemia, conditions that independently increase breast cancer risk over a lifetime. A 2021 analysis in Fertility and Sterility found women with PCOS had a modestly elevated risk of endometrial cancer, driven primarily by chronic anovulation and unopposed estrogen, not IGF-1 per se. Adding a peptide that modulates adipose lipolysis in this hormonal context has not been studied. The theoretical concern is that altered fat cell behavior could affect local estrogen production through changes in adipose aromatase activity.

Perimenopause and Postmenopause

Perimenopausal women represent a large share of AOD-9604 users. This matters for cancer risk because:

1. Breast cancer incidence rises steeply after age 40. The American Cancer Society's 2024 data show the median age at breast cancer diagnosis is 62, meaning perimenopause and the early postmenopausal window coincide with peak incidence.
2. Estrogen from adipose aromatization becomes the dominant sex hormone source after ovarian estrogen declines. Agents that alter adipose tissue architecture or function could theoretically alter local estrogen synthesis, though no data exist to confirm or deny this for AOD-9604 specifically.
3. Women with a personal or strong family history of hormone receptor-positive breast cancer, or those carrying BRCA1/2 variants, have no safety data at all on which to base a decision about AOD-9604.

The North American Menopause Society (NAMS) 2023 position statement on compounded hormones and related peptides notes that compounded preparations lacking strong safety data should not be prescribed to women with elevated hormone-sensitive cancer risk.

Thyroid Health

Women are five to eight times more likely than men to develop thyroid disease. Full-length GH therapy can suppress TSH and alter thyroid hormone conversion. A 2017 review in Endocrine Practice documented this effect in GH-deficient adults receiving replacement therapy. AOD-9604 does not appear to act through the GH receptor and, by extension, probably does not produce this thyroid effect. But "probably" and "no direct evidence" are not the same thing, and women with Hashimoto thyroiditis or treated hypothyroidism using levothyroxine should not assume safety.

Pregnancy and Lactation: AOD-9604 Is Contraindicated

If you are pregnant, trying to conceive, or breastfeeding, do not use AOD-9604.

Pregnancy Category and Human Data

AOD-9604 has no FDA pregnancy category because it has never been approved as a drug. No human pregnancy exposure data exist in any published literature. Animal reproductive toxicology studies specific to AOD-9604 have not been published in peer-reviewed form.

Peptides that modulate adipose metabolism carry theoretical concern during pregnancy because fetal adipose development, placental lipid transfer, and maternal fat stores are tightly regulated processes. Disrupting any of these pathways with an exogenous lipolytic agent at a critical developmental window is a risk no clinician can quantify with current data.

ACOG guidance on medications in pregnancy emphasizes avoiding any agent without established safety data, particularly in the first trimester when organogenesis occurs.

Contraception Requirement

Women of reproductive age using AOD-9604 through a compounding pharmacy should use reliable contraception. If pregnancy is planned, AOD-9604 should be stopped at least one full menstrual cycle before attempting conception, and ideally three months in advance to allow any tissue-level effects to clear.

Lactation Transfer

No lactation transfer studies exist for AOD-9604. Peptides vary widely in their transfer into breast milk depending on molecular weight, lipophilicity, and plasma protein binding. AOD-9604 is a small peptide (approximately 1,815 daltons) that is likely orally bioavailable in infants, meaning any milk transfer could reach systemic circulation in a nursing infant. Given the absence of infant safety data, breastfeeding is incompatible with AOD-9604 use.

Who This Peptide Is and Is Not Right For

Women for Whom AOD-9604 Carries Clearer Concerns

• Women with a personal history of any cancer, particularly breast, endometrial, or ovarian cancer
• Women with BRCA1/2 pathogenic variants or strong family history of hormone-sensitive cancer
• Women who are pregnant, breastfeeding, or actively trying to conceive
• Women with Hashimoto thyroiditis or treated hypothyroidism who have not had thyroid labs assessed in the past six months
• Women in active perimenopause with vasomotor symptoms (hormonal milieu is already unstable; adding an unstudied peptide adds unquantifiable variables)
• Women with a history of insulin resistance or type 2 diabetes who are not under close metabolic monitoring

Women for Whom AOD-9604 Might Be Considered (With Caveats)

No woman is truly an ideal candidate given the evidence gaps, but if a woman is considering AOD-9604 the lowest-concern profile would include: premenopausal age 25 to 45, no personal or family history of hormone-sensitive cancer, no thyroid disease, not pregnant or breastfeeding, metabolically monitored with baseline IGF-1 and fasting insulin, and obtaining the peptide from an FDA-registered 503A compounding pharmacy that provides a certificate of analysis.

Even in this profile, the use is experimental. Any prescribing clinician should document informed consent that includes the absence of long-term human carcinogenicity data.

What the Evidence Gap Means in Practice

Women have been historically under-represented in peptide and growth hormone trials. The National Institutes of Health Office of Research on Women's Health has documented persistent inclusion gaps in endocrine and metabolic drug trials through at least 2020. The AOD-9604 literature is a clear example: the Heffernan 2001 mouse study did not sex-stratify results, and the phase II/III human data from the Metabolic Pharmaceuticals program were never published in a form that allows extraction of female-specific safety signals.

This matters because:

• Women metabolize peptides differently due to differences in body composition, sex hormone concentrations, and renal clearance rates
• Adipose distribution differs between sexes and changes through the reproductive life cycle
• The breast, endometrium, and ovary are estrogen-sensitive tissues that full-length GH affects in ways that AOD-9604's fragment behavior has never been mapped

A 2020 analysis in JAMA Internal Medicine found that drug-related adverse events are 1.5 to 1.7 times more common in women than men, partially attributable to under-representation in dose-finding trials. AOD-9604 was dose-developed in animals and a limited human trial, making female-specific dosing essentially unknown.

Monitoring If You Are Already Using AOD-9604

If you are currently using AOD-9604 and not ready to stop, the minimum monitoring reasonable from a clinical standpoint includes:

• Baseline and six-month IGF-1 level. If IGF-1 rises above the age-adjusted reference range, discontinue and evaluate with your clinician.
• Fasting insulin and glucose. Assess at baseline and at three months.
• Thyroid panel (TSH, free T4, free T3). Baseline for all women; every six months for women with known thyroid disease.
• Breast self-awareness and scheduled mammography. Do not delay recommended screening while using an unstudied compound.
• Cycle tracking. Any new irregularity in menstrual cycle length, flow, or luteal phase symptoms should prompt a pause and clinical evaluation.

Alternatives With a Better Evidence Base for Women

For weight management in women who have not responded to lifestyle alone, FDA-approved GLP-1 receptor agonists including semaglutide (Wegovy) and tirzepatide (Zepbound) have phase III data in women, including published subgroup analyses by sex. The SURMOUNT-1 trial enrolled 2,539 women among its participants, and sex-specific outcomes have been reported. These agents have known safety profiles, real-world pharmacovigilance data, and clear pregnancy contraindication guidance.

For perimenopausal weight gain specifically, NAMS guidelines note that appropriate menopausal hormone therapy can reduce visceral fat accumulation during the menopausal transition, with a favorable cardiovascular and metabolic risk-benefit balance in women under 60 who are within ten years of menopause onset.